StreetInsider.com News Articles

DarioHealth Corp. (DRIO) PT Lowered to $8 at TD Cowen

Wed, 12 Aug 2026 09:43:53 -0400

TD Cowen analyst Charles Rhyee lowered the price target on DarioHealth Corp. (NASDAQ: DRIO) to $8.00 (from $11.00) while maintaining a rating.

DarioHealth (DRIO) Tops Q2 EPS by 40c

Tue, 11 Aug 2026 06:39:58 -0400

DarioHealth (NASDAQ: DRIO) reported Q2 EPS of ($0.85), $0.40 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $6.03 million.

For earnings history and earnings-related data on DarioHealth (DRIO) click here.

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

Form 10-Q DarioHealth Corp. For: Jun 30

Tue, 11 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260811/26900719.html

Form 10-Q DarioHealth Corp. For: Jun 30

Tue, 11 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260811/26900719.html

DarioHealth launches women's health and sleep programs for Q4 2026

Tue, 04 Aug 2026 07:31:30 -0400

DarioHealth Corp. (NASDAQ: DRIO) announced the launch of two new programs, Dario Women and Dario Sleep, expanding its cardiometabolic digital health platform into women's health and sleep management.
Both programs are expected to roll out to the company's Fortune 500 and other enterprise clients in fall 2026. Recurring revenue contribution from the digital health platform is expected to begin in the fourth quarter of 2026, with revenue from provider-backed care services anticipated at the end of 2026 and into early 2027.
Dario Women targets members navigating perimenopause and menopause, life stages associated with metabolic changes and increased cardiometabolic risk. The program includes

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

Tue, 04 Aug 2026 07:30:00 -0400

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy
AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

Tue, 04 Aug 2026 07:30:00 -0400

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy
AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

Tue, 04 Aug 2026 07:30:00 -0400

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy
AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

Tue, 04 Aug 2026 07:30:00 -0400

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy
AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

Tue, 04 Aug 2026 07:30:00 -0400

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy
AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

Tue, 04 Aug 2026 07:30:00 -0400

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy
AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

Tue, 04 Aug 2026 07:30:00 -0400

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy
AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

Tue, 04 Aug 2026 07:30:00 -0400

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy
AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

Tue, 04 Aug 2026 07:30:00 -0400

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy
AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

Tue, 04 Aug 2026 07:30:00 -0400

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy
AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed

DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026

Mon, 03 Aug 2026 06:30:00 -0400

Company to host conference call and webcast at 8:30 a.m. Eastern Time
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 2^nd quarter ended June 30^th, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Tuesday, August 11^th, 2026, before the market opens.

Company to host conference call and webcast at 8:30 a.m. Eastern Time
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 2^nd quarter ended June 30^th, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Tuesday, August 11^th, 2026, before the market opens.

Company to host conference call and webcast at 8:30 a.m. Eastern Time
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 2^nd quarter ended June 30^th, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Tuesday, August 11^th, 2026, before the market opens.

Company to host conference call and webcast at 8:30 a.m. Eastern Time
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 2^nd quarter ended June 30^th, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Tuesday, August 11^th, 2026, before the market opens.